The magnitude of the cytotoxic T lymphocyte response in both immunologically naive mice and in mice primed with a serologically non-cross-reactive influenza A virus was greatly diminished if the virus used for challenge was first incubated with excess hemagglutinin-specific monoclonal antibody. However, the level of T cell stimulation was, when compared with virus stocks that are simply diluted, greater than would be expected from the infectivity titer remaining after exposure to the monoclonal antibody. Also, mice given mixtures of virus and monoclonal antibody were primed for a secondary cytotoxic T lymphocyte response, the frequency of memory T cells being approximately fourfold lower than that found for animals injected with virus alone. The possibility that such virus-antibody mixtures might be of value for immunization is worth further investigation.
The question was asked whether, using a well established cytotoxic T cell assay system (2, 5) , mixtures of hemagglutinin-specific monoclonal antibody and influenza virus could be shown to prime for a cell-mediated immune response. Other inactivation procedures, such as exposure to UV light or Formalin (1, 13, 19) , apparently modify the virus in such a way that it is no longer capable (when inoculated into adult mice) of reproducibly stimulating either a primary cytotoxic T lymphocyte (CTL) response or the development of CTL memory populations. More success was achiFved in the present experiments with virus plus monoclonal antibody, although no firm conclusion could be reached as to whether the virus-monoclonal antibody complexes are able to directly stimulate virus-specific precursor T cells. The possibility that the viral and immunoglobulin molecules may, for instance, dissociate in macrophages before presentation on the cell surface was not addressed here. Even so, it is apparent that the potential use of virus-monoclonal antibody complexes for immunization procedures merits consideration.
MATERIALS AND METHODS
Mice. The BALB/c (H-2") mice were purchased from the Institute for Cancer Research, Philadelphia, Pa., and primed initially with virus as adults (8 to 12 weeks). Viruses Institute, and the A/Hong Kong-X-31 (H3N2) (HK) influenza A virus (12) were grown in embryonated hen eggs by standard techniques. Virus infectivity was determined by the allantois-on-shell method (6) . Mice were injected intraperitoneally with 0.5 or 1.0 ml of a dilution (1:10 to 1:40 in phosphate-buffered saline) of allantoic fluid containing PR8 virus (3,676 hemagglutinating units/ml). This represented a dose of approximately 180 hemagglutination units, or a 106 50o egg infective dose.
Monodonal antibody. The H2/4B3 (-y2b) monoclonal antibody, also referred to as Sa-1 (10), was produced by fusion of BALB/c PR8 influenza virus immune lymphocytes with P3/X63-Ag8 myeloma cells (9) . This antibody is specific for the viral hemagglutinin of the PR8 influenza virus and has been further characterized by radioimmunoassay with a set of mutant PR8 viruses (10) . The H2/4B3 ascitic fluid used contained 13.0 mg of immunoglobulin per ml, at a titer of 110,000 hemagglutinin inhibiting units per mg, as determined by the method of W. Gerhard and J. Yewdell (7) . Mice were inoculated intraperitoneally with 0.5 or 1.0 ml of a virus-antibody mixture that had been held on ice for 1 h.
Cytotoxic T celi assay. Single cell suspensions were prepared by homogenizing one to four spleens. The viability of washed cells was determined by trypan blue exclusion, and assays were generally done at effector-to-target (E:T) ratios of 50:1 and 100:1. Most results presented are for E:T ratios of 100:1.
The P815 (H-2d) target cells were harvested, pelleted, washed, and then labeled for 1 h at 37°C with 0 ± 0 a BALB/c mice were primed with 150 hemagglutinating units of HK-X-31 more than 1 month previously and challenged intraperitoneally with 1.0 ml of the virus-antibody mixture, which had been held on ice for 1 h. Single cell suspensions of spleen were assayed for CTL activity 4 days later.
b Dilution of mouse ascitic fluid containing 13 mg of H2/4B3 per ml. Titrated by the allantois-on-shell method (7) , with results calculated according to Reed and Muench (12a) . d Measured at an E:T ratio of 100:1. Numbers in brackets represent the percent reduction in cytotoxicity relative to results for no antibody. e NI, Normal or uninfected targets.
plates (Linbro Chemical Co., New Haven, Conn.) in 100-,ul portions to give 104 cells per assay well. The effectors were then added in a further 100-,u portion, and the plates were incubated for 9 h at 37°C in a humidified atmosphere containing 6% CO2 in air.
Then, 100 RI1 of supernatant was removed from each well and counted in a gamma scintillation spectrometer. Results are expressed as percent mean ± standard error of specific 5tCr release for replicates of four wells where: % specific 51Cr release = E(cpm experimental) -(cpm spontaneous)] x 100 (cpm maximum) -(cpm spontaneous)
Maximum release was determined for cultures to which 100 ,u1 of 0.028% cetrimide (hexadecyltrimethylammonium bromide, Eastman Kodak, Rochester, N.Y.) was added, and spontaneous release was measured for wells containing an additional 100 ,u1 of medium. The percent reduction in cytotoxicity was calculated as (1specific 51Cr release for effectors from antibodytreated mice/specific 51Cr release for effectors from untreated control mice) x 100.
Limiting dilution cultures. Limiting numbers of BALB/c spleen cells were cultured in 96-well microtiter plates with 2 x 105 1,500-rad-irradiated BALB/c stimulator spleen cells infected with either A/PR8 or A/HK influenza virus (17, 20; J. A. Owen, M. Allouche, and P. C. Doherty, Cell. Immunol., in press). Cells were portioned in 0.1 ml per well of RPMI 1640 supplemented with 10% fetal calf serum, 5 x 10-5 M 2mercaptoethanol, 50 p.g of gentamicin per ml, 4 mM glutamine, and 25% (vol/vol) of a rat concanavalin A supernatant. The concanavalin A was blocked by the addition of 10 mg of methyl-Dmannoside per ml. CTL responses were not generated by stimulator cells plated alone. After a 6-day culture, cells in each well were divided in three portions. To each portion, we added 5 x 103 51Cr-labeled P815 target cells (PR8 infected, HK infected, or uninfected). After a 7-h incubation at 37°C, 100 p.l of supernatant was removed from each well for gamma counting. Cultures were considered positive if at least 20% virusspecific lysis was detected on either PR8 or HK targets. The frequency of CTL precursors was calculated by plotting the percentage of nonresponding cultures versus the number of responding cells per well. Clones were considered specific for either PR8 or HK if percent lysis PR8infected cellspercent lysis uninfected cells/ percent lysis HK-infected cellspercent lysis uninfected cells was >4 (PR8-specific) or <0.25 (HK-specific), respectively.
Other patterns of cytotoxicity were scored as cross-reactive.
RESULTS
Elicitation of a CTL response. Inoculation of both HK-X-31 (H3N2)-primed (Table 1 ) and unprimed ( Fig. 1 ) BALB/c mice with mixtures of H2/4B3 and PR8 (H1N1) generated a low level of CTL response when doses of monoclonal antibody much greater than those required to neutralize all infectivity were used for challenge (1:10 and 1:100 dilutions, 1,300 and 130 p.g; Table 1 ). The secondary CTL response on day 4 was approximately 80% less (Table 1) , but the level of lysis seen for primary CTL (Fig. 1 ) was also much reduced for mice given virus and monoclonal antibody rather than virus alone. It should be recognized that the virus was injected in the presence of excess monoclonal antibody, which at the higher concentrations used would have persisted in the circulation for the 4 or 5 days during which T cells were stimulated (N. S. 646 GREENSPAN Even so, reducing the level of viral infectivity by a factor of 100 (1:10,000 dilution of H2/4B3; Table 1 ) still resulted in the generation of a potent, secondary CTL response. Also, the level of effector T cell generation observed after neutralization of all infectivity (1:1,000 dilution of H2/4B3, 10,000-fold reduction in virus titer; Table 1) was at least as great as that seen when the virus titer was reduced only 16-fold by diluting the inoculum (compare 1:20 and 1:320 dilution; Fig. 2 ). Thus, though the capacity of virus to stimulate a secondary CTL response was greatly diminished by the presence of excess monoclonal antibody, the potency of the challenge with the virus-monoclonal antibody mixture was greater than would be expected from a simple infectivity titration (Table 1, Fig. 2 ).
Priming T cell populations. Mice primed with PR8 (H1N1) that was completely neutralized by the presence of H2/4B3 (see Table 2 , experiment 1; 1:10 dilution) generated a secondary CTL response 4 days after challenge with HK-X-31. This response clearly exceeded that of control mice not primed with any virus, and which were therefore generating a primary response ( Table  2 , experiment 3), and that of control mice that were neither primed nor challenged with virus ( Table 2 , experiment 4). These results are consistent with previous data comparing the kinetics of primary and secondary in vivo CTL responses to influenza A viruses (2) . All dilutions of antibody plus virus supported some priming for a secondary response, although fluctuations in the levels of cytotoxicity among the test groups were apparent.
To confirm and quantitate the priming capacity of antibody-virus complexes, limiting dilution analysis was undertaken. The analysis of spleen populations from mice that were primed by inoculation of virus plus vast excess of monoclonal antibody showed that the frequency of memory T cell clones was reduced approximately fourto fivefold below that observed for those stimulated with virus alone, but was significantly higher than unprimed controls ( Table 3) a BALB/c mice primed intraperitoneally with PR8 influenza virus mixed with dilutions of ascitic fluid containing the H2/4B3 monoclonal antibody (13 mg/ml). The virus-antibody mixtures were held on ice for 1 h before inoculation. These mice were then challenged after at least 1 month by intraperitoneal inoculation of 150 HAU of HK-X-31, and spleen cells were assayed (day 4) on virus-infected P815 targets. Pools of 2 or 3 spleens were used in experiments 1 and 4, and individual spleens were tested in experiments 2 and 3.
b Measured at an E:T ratio of 100:1. I NI, Normal or uninfected targets. d This dose equivalent to 1:1,000 dilution of ascitic fluid, completely neutralized viral infectivity (Table 1) .
targets infected with the PR8 and HK-X-31 viruses ( Table 4 ). In a separate limiting dilution experiment (data not shown) mice were primed with UVinactivated virus in vivo and restimulated with normal virus in vitro. Three of four mice tested showed no response exceeding that of unprimed controls, suggesting that memory cells had not been generated. This promotes the method of priming with antibody-virus complexes as being superior for the induction of CTL memory with neutralized virus. DISCUSSION These studies were, of course, one-dimensional in that we only studied the cell-mediated immune response. Even so, they point to the possibility that an approach to vaccination with virus-monoclonal antibody mixtures is worth exploring in a much more comprehensive way. Evidently, virus complexed with monoclonal antibody is able to both reach the relevant stimulator cells and to ultimately be presented in a way that is sufficient for the induction of T cell memory.
The PR8 influenza A virus used was completely neutralized by exposure to high titers of the H2/4B3 monoclonal antibody. Even so, the frequency of influenza virus variants that are not neutralized by a particular monoclonal antibody may be as high as 1 in 105 or 1 in 106 infectious units (8) (9) (10) . However, influenza A viruses can- a This is an analysis of T cell specificity patterns for the T cell populations described in Table 3 . A particular clone was arbitrarily characterized as specific if there was a fourfold difference in the level of specific 5tCr release following assay with the two targets.
not be shown to initiate productive infection of either mouse lymphoid tissue or mouse macrophages (15, 16, 18) . Also, the strict dose dependence of effector CTL generation in the influenza model is quite different from the situation observed for viruses such as lymphocytic choriomeningitis virus (4), which multiply extensively after inoculation of even a minimal infe,ctious dose. It thus seems extremely unlikely that any influenza virus variants that were in the inoculum and were not neutralized by the monoclonal antibody could have been present in sufficient concentration to cause the generation of significant numbers of memory T cells. The in vivo interactions between monoclonal antibodies, viruses, antigen-presenting cells, and T cells are likely to be complex and difficult to analyze. It has been found, in a limited number of previous experiments (N. S. Greenspan, Ph.D. thesis), that a large dose of monoclonal antibody given shortly before virus greatly decreases the magnitude of the primary CTL response. This is probably analogous to the situation described here for the injection of a virus-monoclonal antibody mixture. Administration of the same monoclonal antibody from 3 to 48 h after challenge with virus may also cause some diminution of both the primary and secondary CTL response (11) , with a tendency to cause a greater reduction in effector function associated with the subtype-specific rather than the cross-reactive T cell subsets (2, 5) . Monoclonal antibody given after virus probably acts by binding to antigen presented on the surface of the stimulator cells. This effect could also be operating in the present studies for experiments where large doses of monoclonal antibody were used, as the antibody persists at high titer for at least 5 days (N. S. Greenspan, Ph.D. thesis). No attempt has yet been made to assess the immunogenic properties of pelleted, washed influenza A virus-monoclonal antibody complexes.
Even so, it is important that we should understand better the nature of the response to virus (and other antigens recognized by T cells) in animals circulating excess monoclonal antibody. Postexposure administration of monoclonal antibodies can protect mice from the fatal consequences of infection with both influenza and rabies viruses (3; P. C. Doherty, N. Greenspan, A. D. Lopes and W. Gerhard in T. K. Eisenstein and H. Friedman, ed., Host Defenses to Intracellular Pathogens, in press). Therapy with monoclonal antibodies has already been attempted for patients with various leukemias and lymphomas (14) . We need to clearly understand the longand short-term effects of such procedures on the overall host response.
